Oncolytic herpes simplex virus and therapeutic uses thereof

Patent metadata

Field	Value
Publication number	US-11147846-B2
Application number	US-201916578178-A
Country	US
Kind code	B2
Filing date	Sep 20, 2019
Priority date	Sep 8, 2011
Publication date	Oct 19, 2021
Grant date	Oct 19, 2021

Abstract

The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, for example, for treating cancer in a subject, are also provided.

First claim

What is claimed is:

1. A variant oncolytic herpes simplex virus (HSV) comprising functionally inactive ICP34.5 encoding genes, wherein at least one of the ICP34.5 encoding genes is rendered functionally inactive by the insertion of an expression cassette comprising:
(a) a US11 encoding polynucleotide operably associated with an immediate early (IE) promoter;
(b) a virus-derived heterologous transporter associated with antigen presentation (TAP) inhibitor encoding polynucleotide; and
(c) a granulocyte macrophage colony stimulating factor (GM-CSF), tumor necrosis factor (TNF)-alpha, Interleukin (IL)-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, granulocyte colony stimulating factor (G-CSF), Interferon (IFN)-α, IFN-y, IL-20 (MDA-7), B7-1 (CD80) or B7-2 (CD86) encoding polynucleotide.

2. The variant HSV of claim 1 , wherein the variant HSV is derived from HSV-1.

3. The variant HSV of claim 2 , wherein the variant HSV is derived from wild-type HSV-1, HSV-1 strain F, HSV-1 strain 17, HSV-1 KOS, HSV-1 strain Patton, or an HSV-1 clinical strain.

4. The variant HSV of claim 1 , wherein the variant HSV is at least 70% identical to HSV-1 or HSV-2.

5. The variant HSV of claim 1 , wherein the variant HSV is at least 70% identical to SEQ ID NO: 1.

6. The variant HSV of claim 1 , wherein the heterologous TAP inhibitor is a herpes virus UL49.5 polypeptide, a cytomegalovirus (CMV) US6 polypeptide, or a BNLF2a polypeptide.

7. The variant HSV of claim 6 , wherein the UL49.5 polypeptide is derived from bovine herpes virus, pseudorabies virus, equine herpes virus 1, equine herpes virus 4, bubaline herpesvirus 1, cervid herpes virus 1, or felid herpesvirus 1.

8. The variant HSV of claim 7 , wherein the UL49.5 polypeptide is derived from bovine herpesvirus.

9. The variant HSV of claim 1 , wherein the heterologous TAP inhibitor encoding polynucleotide is operably associated with a cellular or viral promoter.

10. The variant HSV of claim 9 , wherein the cellular or viral promoter is a CMV promoter, Moloney Murine Leukemia Virus (MMLV) Long Terminal Repeat (LTR) promoter, a Rous Sarcoma Virus (RSV) promoter, an α0 promoter, an α4 promoter, an α22 promoter, an α27 promoter, an α47 Immediate Early (IE) promoter, or an Elongation Factor 1 alpha (EF1α).

11. The variant HSV of claim 1 , wherein the variant HSV comprises an intact US12 encoding gene.

12. The variant HSV of claim 1 , wherein the variant HSV comprises an additional US11 encoding polynucleotide operably associated with a late promoter.

13. The variant HSV of claim 1 , wherein the IE promoter is an α0 promoter, an α4 promoter, an α22 promoter, an α27 promoter, an α47 IE promoter, an EF1α promoter, or a CMV promoter.

14. The variant HSV of claim 1 , wherein the granulocyte macrophage colony stimulating factor (GM-CSF), tumor necrosis factor (TNF)-alpha, Interleukin (TL)-1, IL-2, IL-3, TL-4, TL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, granulocyte colony stimulating factor (G-CSF), Interferon (IFN)-α, IFN-y, IL-20 (MDA-7), B7-1 (CD80) or B7-2 (CD86) encoding polynucleotide is operably associated with a cellular or viral promoter.

15. The variant HSV of claim 14 , wherein the cellular or viral promoter is a CMV promoter, a MMLV LTR promoter, a RSV promoter, an α0 promoter, an α4 promoter, an α22 promoter, an α27 promoter, an α47 IE promoter, or an EF1α promoter.

16. The variant HSV of claim 1 , wherein the granulocyte macrophage colony stimulating factor (GM-CSF), tumor necrosis factor (TNF)-alpha, Interleukin (IL)-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, granulocyte colony stimulating factor (G-CSF), Interferon (IFN)-α, IFN-y, IL-20 (MDA-7), B7-1 (CD80) or B7-2 (CD86) encoding polynucleotide is operably associated with an inducible promoter.

17. The variant HSV of claim 1 , wherein the US11 encoding polynucleotide, the heterologous TAP inhibitor encoding polynucleotide, and the granulocyte macrophage colony stimulating factor (GM-CSF), tumor necrosis factor (TNF)-alpha, Interleukin (IL)-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, granulocyte colony stimulating factor (G-CSF), Interferon (IFN)-α, IFN-y, IL-20 (MDA-7), B7-1 (CD80) or B7-2 (CD86) encoding polynucleotide are inserted in the expression cassette in the same orientation.

18. The variant HSV of claim 17 , wherein the US11 encoding polynucleotide, the heterologous TAP inhibitor encoding polynucleotide, and the granulocyte macrophage colony stimulating factor (GM-CSF), tumor necrosis factor (TNF)-alpha, Interleukin (IL)-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, granulocyte colony stimulating factor (G-CSF), Interferon (IFN)-α, IFN-y, IL-20 (MDA-7), B7-1 (CD80) or B7-2 (CD86) encoding polynucleotide are operably associated with the same promoter.

19. The variant HSV of claim 18 , wherein the same promoter is selected from a CMV promoter, a MMLV LTR promoter, a RSV promoter, an α0 promoter, an α4 promoter, an α22 promoter, an α27 promoter, an α47 IE promoter, or an EF1α promoter.

20. A pharmaceutical formulation comprising the variant HSV of claim 1 and a pharmaceutically acceptable carrier.

21. A method of treating a patient suffering from cancer comprising administering to the patient the pharmaceutical composition of claim 20 .

22. The method of claim 21 , wherein the cancer is selected from breast, brain, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, or uterus.

23. The method of claim 22 , wherein the cancer is selected from Medulloblastoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, a primary brain tumor, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, testicular cancer, lymphomas, thyroid cancer, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine and exocrine pancreas, and prostate cancer.

Assignees

• Univ New York
• Benevir Biopharm Inc

Inventors

• Mohr Ian J
• Mulvey Matthew

Classifications

• C12N15/86

  Viral vectors · CPC title

• A61K35/763 Primary

  Herpes virus · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C12N2710/16632

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title